Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real‐life clinical practice
Journal of the European Academy of Dermatology and Venereology · 2024-09 · 38 (9) · 1783-1790
DOI: 10.1111/jdv.19782 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 28.12.2023. Verfasst von E Muñoz-Aceituno und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria La Princesa, Madrid, Spain. Hauptthemen laut MEDLINE: Psoriasis, Antibodies, Monoclonal, Humanized, Polymorphism, Single Nucleotide. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Instituto de Salud Carlos III, Fondo Europeo de Desarrollo Regional, Novartis.
Abstract (Originalsprache)
Background
Prediction of the response to a biological treatment in psoriasis patients would allow efficient treatment allocation.
Objective
To identify polymorphisms associated with secukinumab response in psoriasis patients in a daily practice setting.
Methods
We studied 180 SNPs in patients with moderate‐to‐severe plaque psoriasis recruited from 15 Spanish hospitals. Treatment effectiveness was evaluated by absolute PASI ≤3 and ≤1 at 6 and 12 months. Individuals were genotyped using a custom Taqman array. Multiple logistic regression models were generated. Sensitivity, specificity and area under the curve (AUC) were analysed.
Results
A total of 173 patients were studied at 6 months, (67% achieved absolute PASI ≤ 3 and 65% PASI ≤ 1) and 162 at 12 months (75% achieved absolute PASI ≤ 3 and 64% PASI ≤ 1). Multivariable analysis showed the association of different sets of SNPs with the response to secukinumab. The model of absolute PASI≤3 at 6 months showed best values of sensitivity and specificity. Four SNPs were associated with the capability of achieving absolute PASI ≤ 3 at 6 months. rs1801274 ( FCGR2A ), rs2431697 ( miR‐146a ) and rs10484554 ( HLCw6 ) were identified as risk factors for failure to achieve absolute PASI≤3, while rs1051738 ( PDE4A) was protective. AUC including these genotypes, weight of patients and history of biological therapy was 0.88 (95% CI 0.83–0.94), with a sensitivity of 48.6% and specificity of 95.7% to discriminate between both phenotypes.
Conclusion
We have identified a series of polymorphisms associated with the response to secukinumab capable of predicting the potential response/non‐response to this drug in patients with plaque psoriasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria La Princesa, Madrid, Spain.
- Departamento de Ciencias Farmacéuticas y de la Salud, Facultad de Farmacia, Universidad San Pablo-CEU, CEU, CEU Universities Madrid, Madrid, Spain.
- Department of Dermatology, Hospital Universitario y Politécnico La Fe, Instituto de Investigación Sanitaria La Fe, Valencia, Spain.
- Department of Dermatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
- Department of Dermatology, Hospital Virgen de la Victoria, Málaga, Spain.
- Department of Dermatology, Hospital Universitario 12 de Octubre, Madrid, Spain.
ORCID-Profile: B Butrón-Bris, M C Ovejero-Benito, A Sahuquillo-Torralba, R Rivera-Diaz, J Riera-Monroig, P de la Cueva, R Ruiz-Villaverde, M Llamas-Velasco, E Daudén-Tello, H de la Fuente
Förderung
- Instituto de Salud Carlos III
- Fondo Europeo de Desarrollo Regional
- Novartis
- European Regional Development Fund
Zitieren
APA
Muñoz-Aceituno, E., Butrón-Bris, B., Ovejero-Benito, M. C., Sahuquillo-Torralba, A., Baniandrés Rodríguez, O., Herrera-Acosta, E., Rivera-Diaz, R., Ferran, M., Sánchez-Carazo, J. L., Riera-Monroig, J., Pujol-Montcusí, J., Vidal, D., de la Cueva, P., García-Bustinduy, M., Ruiz-Villaverde, R., Ballescà, F., Llamas-Velasco, M., Navares, M., Palomar-Moreno, I., …, & de la Fuente, H. (2024). Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real‐life clinical practice. Journal of the European Academy of Dermatology and Venereology, 38(9), 1783-1790. https://doi.org/10.1111/jdv.19782
Vancouver
Muñoz-Aceituno E, Butrón-Bris B, Ovejero-Benito MC, Sahuquillo-Torralba A, Baniandrés Rodríguez O, Herrera-Acosta E, et al. Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real‐life clinical practice. Journal of the European Academy of Dermatology and Venereology. 2024;38(9):1783-1790. doi:10.1111/jdv.19782
BibTeX
@article{MuozAceituno2024,
author = {Muñoz-Aceituno, E and Butrón-Bris, B and Ovejero-Benito, M C and Sahuquillo-Torralba, A and Baniandrés Rodríguez, O and Herrera-Acosta, E and Rivera-Diaz, R and Ferran, M and Sánchez-Carazo, J L and Riera-Monroig, J and Pujol-Montcusí, J and Vidal, D and de la Cueva, P and García-Bustinduy, M and Ruiz-Villaverde, R and Ballescà, F and Llamas-Velasco, M and Navares, M and Palomar-Moreno, I and Sánchez-García, I and García-Martínez, J and Novalbos, J and Zubiaur, P and Abad-Santos, F and Daudén-Tello, E and de la Fuente, H},
title = {Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real‐life clinical practice},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2024},
volume = {38},
number = {9},
pages = {1783--1790},
doi = {10.1111/jdv.19782}
}
EUVIMED